SAN CLEMENTE, Calif: ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases announced today that it has received a significant order for its ReShape Integrated Dual Balloon System from Al Zahrawi Medical, a healthcare focused company specializing in medical, surgical, diagnostic and analytical lab and nuclear medicine supplies with presence throughout the United Arab Emirates (UAE) and Qatar.
This order, the second since Al Zawhari's initial stocking order in August 2017, is to support increased demand for the Reshape Integrated Dual Balloon System from a leading hospital customer's growing bariatric program in Dubai.
Obesity in the UAE has been estimated to be twice the worldwide rate. While close to 30% of the global population is estimated to be obese, according to a University of Washington's Institute for Health Metrics and Evaluation report from 2013, more than 66% of men and 60% of women in the UAE were estimated to be obese.
Over 5,000 weight loss surgeries were performed in the UAE in 2015, an increase of more than 30% from 2014, as reported by the Emirates Obesity Association under the Emirates Medical Association.
